Literature DB >> 21808988

Recent developments in nongastric mucosa-associated lymphoid tissue lymphoma.

Marlene Troch1, Barbara Kiesewetter, Markus Raderer.   

Abstract

Guidelines and algorithms for the management of gastric mucosa-associated lymphoid tissue (MALT) lymphoma have been developed in the recent past, but the situation regarding nongastric MALT lymphomas is much more complicated. Owing to the heterogeneity of MALT lymphomas arising in various organs, different approaches to treatment have been applied, mostly in an uncontrolled fashion. In the recent past, for example, attempts to use antibiotic therapy in managing ocular adnexal MALT lymphomas have been reported, with response rates varying between 0% and 60% with the use of doxycycline or, more rarely, clarithromycin. Currently, antibiotic therapy remains experimental, with conflicting data and apparent geographic variations. In addition, there is no clear consensus whether radiation or systemic therapy is more effective in MALT lymphomas at different locations, including the lung and the ocular adnexa. This review highlights and briefly discusses some recent developments in the management of nongastric MALT lymphomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21808988     DOI: 10.1007/s11899-011-0095-9

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  25 in total

1.  Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial.

Authors:  Silvia Govi; Giuseppina P Dognini; Giada Licata; Roberto Crocchiolo; Antonio Giordano Resti; Maurilio Ponzoni; Andrés J M Ferreri
Journal:  Br J Haematol       Date:  2010-04-28       Impact factor: 6.998

2.  EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT.

Authors:  A Ruskoné-Fourmestraux; W Fischbach; B M P Aleman; H Boot; M Q Du; F Megraud; C Montalban; M Raderer; A Savio; A Wotherspoon
Journal:  Gut       Date:  2011-02-11       Impact factor: 23.059

3.  Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.

Authors:  Sung Yong Oh; Won Seog Kim; Jin Seok Kim; Seok Jin Kim; Hyuk-Chan Kwon; Dae Ho Lee; Jong Ho Won; In Gyu Hwang; Min Kyoung Kim; Soon Il Lee; Yee Soo Chae; Deok-Hwan Yang; Gyeong-Won Lee; Chul Won Choi; Jinny Park; Cheolwon Suh; Hyo-Jin Kim
Journal:  Ann Hematol       Date:  2009-12-19       Impact factor: 3.673

4.  Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).

Authors:  A Conconi; G Martinelli; A Lopez-Guillermo; P L Zinzani; A J M Ferreri; L Rigacci; L Devizzi; U Vitolo; S Luminari; F Cavalli; E Zucca
Journal:  Ann Oncol       Date:  2010-09-01       Impact factor: 32.976

5.  High relapse rate in patients with MALT lymphoma warrants lifelong follow-up.

Authors:  Markus Raderer; Berthold Streubel; Stefan Woehrer; Andreas Puespoek; Ulrich Jaeger; Michael Formanek; Andreas Chott
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

6.  Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy.

Authors:  Jayant S Goda; Mary Gospodarowicz; Melania Pintilie; Woodrow Wells; David C Hodgson; Alexander Sun; Micheal Crump; Richard W Tsang
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

7.  Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.

Authors:  Soley Bayraktar; Ulas D Bayraktar; Alexandra Stefanovic; Izidore S Lossos
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

8.  Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma.

Authors:  Birgit Grünberger; Stefan Wöhrer; Berthold Streubel; Michael Formanek; Ventzislav Petkov; Andreas Puespoek; Michael Haefner; Michael Hejna; Ulrich Jaeger; Andreas Chott; Markus Raderer
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

9.  Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.

Authors:  Antonio Salar; Eva Domingo-Domenech; Cristina Estany; Miguel A Canales; Fernando Gallardo; Octavio Servitje; Guadalupe Fraile; Carlos Montalbán
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

10.  A phase II study of bortezomib in patients with MALT lymphoma.

Authors:  Marlene Troch; Constanze Jonak; Leonhard Müllauer; Andreas Püspök; Michael Formanek; Wolfgang Hauff; Christoph C Zielinski; Andreas Chott; Markus Raderer
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.